BiomX
BiomX
Microbiome drug discovery company developing customized phage therapies for chronic diseases.
About
BiomX is a microbiome drug discovery company focused on developing customized phage therapies. They target and destroy harmful bacteria implicated in chronic diseases such as inflammatory bowel disease (IBD) and cancer. The company discovers and validates proprietary bacterial targets and customizes natural and engineered phages to address these conditions.
Key facts
- Website
- thlsq.ai
- Headquarters
- Ness Ziona, Israel
- Founded
- 2017
- Employees
- 104
- Total funding
- $56M (Series B)
- Valuation
- Private
- Business model
- B2B
- Tags
- HealthcareDrug DiscoveryBiotechPhage TherapyMicrobiome Engineering
Funding rounds
Tech stack
Detected on thlsq.ai, last scanned 22 Sept 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Tag Manager
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
Add first review
Frequently asked
How much funding has BiomX raised?
BiomX has raised a total of $56M in funding. The most recent round on record is Series B.
How many employees does BiomX have?
BiomX has approximately 104 people on record.